Elsevier

Clinical Therapeutics

Volume 25, Issue 6, June 2003, Pages 1786-1805
Clinical Therapeutics

Editorial
The effect of anemia treatment on selected health-related quality-of-life domains: A systematic review

https://doi.org/10.1016/S0149-2918(03)80170-4Get rights and content

Abstract

Background: Anemia is a reduction in the oxygen-carrying capacity of red blood cells that results in a variety of symptoms, including dyspnea, headaches, light-headedness, and fatigue. Although anemia has been associated with reduced health-related quality of life (HRQoL), its treatment has not yet been consistently shown to improve HRQoL.

Objective: This systematic review of the literature was conducted to determine whether the treatment of anemia improves HRQoL domains, regardless of the type of underlying disease.

Methods: Data for this review were drawn from the clinical trial databases from 2 previous systematic literature reviews of erythropoiesis-stimulating protein treatment for renal insufficiency- and cancer-related anemia, both spanning the period January 1, 1980, through December 31, 2001. MEDLINE, Cancerlit, and Current Contents/Clinical Medicine were searched using the combined terms erythropoietin, kidney failure, neoplasms, and anemia. The reference lists of all identified articles were searched manually for additional relevant papers. The review included prospective studies that reported both HRQoL and hematocrit (Hct) in patients with cancer or renal insufficiency who received treatment for anemia with an erythropoiesis-stimulating protein. HRQoL was categorized by domain (overall, energy/fatigue, physical, activity); changes in HRQoL domains were expressed as effect sizes and meta-analyzed, as were correlation coefficients. The effects on HRQoL of dropout rate, study duration, baseline Hct, and change in Hct were examined in meta-regression analyses.

Results: Sixteen studies each were identified in patients with renal insufficiency (N = 2253) and patients with cancer (N = 10,695). The treated groups included 11,710 patients, and the control groups included 1238 patients. The baseline Hct in all treated groups averaged 26.0%: 28.3% in the group with cancer and 24.4% in the group with renal insufficiency. The mean improvement in Hct from baseline to the end of treatment was 8.3% (range, 1.0%–16.5%) in treated patients and 1.0% (range, 0.0%–3.3%) in controls. The Hct changes were similar in treated patients with cancer and treated patients with renal insufficiency, as was the HRQoL effect size (0.43). Dropout rate and study duration were not significant predictors of HRQoL changes, but change in Hct was a significant predictor in both conditions. Meta-analysis of the correlation coefficients, adjusting for HRQoL domains, showed a consistent and significant positive correlation between change in Hct and change in HRQoL (P < 0.001).

Conclusion: The consistency in both direction and magnitude of effect across many studies and thousands of patients supports the hypothesis that treatment of anemia with erythropoiesis-stimulating protein improves selected HRQoL domains in patients with renal insufficiency- or cancer-related anemia.

References (67)

  • S.B. Yellen et al.

    Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system

    J Pain Symptom Manage.

    (1997)
  • W.M. McClellan et al.

    Functional status and quality of life: Predictors of early mortality among patients entering treatment for end stage renal disease

    J Clin Epidemiol.

    (1991)
  • R. Jaeschke et al.

    Measurement of health status. Ascertaining the minimal clinically important difference

    Control Clin Trials

    (1989)
  • D. Cella

    The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: A new tool for the assessment of outcomes in cancer anemia and fatigue

    Semin Hematol.

    (1997)
  • J. Glaspy et al.

    Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice

    J Clin Oncol.

    (1997)
  • D.F. Cella

    Measuring quality of life in palliative care

    Semin Oncol.

    (1995)
  • D.F. Cella et al.

    Measuring quality of life: 1995 Update

    Oncology (Huntingt)

    (1995)
  • J. Seidenfeld et al.

    Epoetin treatment of anemia associated with cancer therapy: A systematic review and meta-analysis of controlled clinical trials

    J Natl Cancer Inst.

    (2001)
  • D.J. Cook et al.

    Systematic reviews: Synthesis of best evidence for clinical decisions

    Ann Intern Med.

    (1997)
  • J. Cohen

    Statistical Power Analysis for the Behavioral Sciences

    (1988)
  • N. Mantel et al.

    Statistical aspects of the analysis of data from retrospective studies of disease

    J Natl Cancer Inst.

    (1959)
  • L.V. Hedges et al.

    Statistical Methods for Meta-Analysis

    (1985)
  • H. Cooper et al.
  • Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis

    BMJ

    (1990)
  • J. Auer et al.

    Quality of life improvements in CAPD patients treated with subcutaneously administered erythropoietin for anemia

    Perit Dial Int.

    (1992)
  • K.M. Beusterien et al.

    The effects of recombinant human erythropoietin on functional health and well-being in chronic dialysis patients

    J Am Soc Nephrol.

    (1996)
  • J.W. Eschbach et al.

    Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a Phase III multicenter clinical trial

    Ann Intern Med.

    (1989)
  • D.C. Harris et al.

    Low dose erythropoietin in maintenance haemodialysis: Improvement in quality of life and reduction in true cost of haemodialysis

    Aust N Z J Med.

    (1991)
  • I. Hurtado et al.

    Study of quality of life of patients on maintenance hemodialysis before and after the use of erythropoietin [in Spanish]

    Nefrologia

    (2000)
  • L.P. McMahon et al.

    Effects of haemoglobin normalization on quality of life and cardiovascular parameters in end-stage renal failure

    Nephrol Dial Transplant

    (2000)
  • F. Moreno et al.

    Increasing the hematocrit has a beneficial effect on quality of life and is safe in selected hemodialysis patients

    J Am Soc Nephrol.

    (2000)
  • N. Muirhead et al.

    Safety and efficacy of recombinant human erythropoietin in correcting the anemia of patients with chronic renal allograft dysfunction

    J Am Soc Nephrol.

    (1994)
  • N. Muirhead et al.

    Comparison of subcutaneous and intravenous recombinant human erythropoietin for anemia in hemodialysis patients with significant comorbid disease

    Am J Nephrol.

    (1992)
  • Cited by (0)

    View full text